In support of this network having a pro-tumourfunction, inhibition of CXCL1 and CXCL2 receptor CXCR2 is sufficient to suppressinflammation-driven skin and intestinal cancers19.Furthermore, s100a9−/− mice areprotected against cancers of inflammatory origin, including breast, pancreaticand colitis-associated tumours25, 26, 27, although loss ofS100A9 is associated with susceptibility to experimental skin cancer28. This evidence concerns the gene CXCR2 and cancer.